Selecta Biosciences (SELB) Earns Daily Media Sentiment Rating of 0.04
News coverage about Selecta Biosciences (NASDAQ:SELB) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Selecta Biosciences earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.9200405894816 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- Selecta Biosciences Inc (SELB) Expected to Post Earnings of -$0.72 Per Share (americanbankingnews.com)
- Urea Cycle Disorders Market Pipeline Therapeutics 2018 Product Description, Key Companies and Table of Content (dailyjournalnow.com)
- JPMorgan Chase & Co. Acquired $4215000 in Selecta Biosciences Inc. (SELB) (bharatapress.com)
- Notable Performance Spotlight: Selecta Biosciences, Inc. (SELB) (nysewired.com)
- Global Ornithine-Transcarbamylase Deficiency Market Research: Growth Opportunities by Regions, Types … (thechronicleindia.com)
Shares of SELB stock traded down $0.36 during trading hours on Friday, hitting $12.76. 73,454 shares of the company’s stock were exchanged, compared to its average volume of 213,695. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.20 and a current ratio of 7.20. The stock has a market capitalization of $285.19 million, a PE ratio of -3.99 and a beta of -3.64. Selecta Biosciences has a 52 week low of $7.95 and a 52 week high of $24.02.
A number of analysts have weighed in on SELB shares. Canaccord Genuity upped their price target on Selecta Biosciences from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, May 23rd. ValuEngine upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Zacks Investment Research upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. Mizuho restated a “buy” rating and set a $30.00 target price on shares of Selecta Biosciences in a report on Wednesday, April 11th. Finally, Janney Montgomery Scott initiated coverage on Selecta Biosciences in a report on Wednesday, June 27th. They set a “buy” rating and a $33.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $28.25.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Featured Article: Book Value Of Equity Per Share – BVPS Explained
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.